Postmenopausal Osteoporosis Treatment Market Forecast 2024-2033: Projected CAGR, Key Drivers, And Trends

Postmenopausal osteoporosis treatment refers to medical interventions and strategies to manage and prevent bone loss and fractures in women after menopause. Postmenopausal osteoporosis is characterized by decreased bone density and increased susceptibility to fractures due to hormonal changes after menopause.

Sizing and Forecast
The postmenopausal osteoporosis treatment market size has grown strongly in recent years. It will grow from $9.49 billion in 2023 to $10.03 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%.  The  growth in the historic period can be attributed to aging population, hormone replacement therapy, increased awareness, fracture risk reduction, nutritional supplements.

The postmenopausal osteoporosis treatment market size is expected to see strong growth in the next few years. It will grow to $12.38 billion in 2028 at a compound annual growth rate (CAGR) of 5.4%.  The growth in the forecast period can be attributed to healthcare infrastructure growth, increased screening programs, precision medicine approaches, biosimilars in osteoporosis treatment, bone health in women’s health programs, digital health integration, regenerative medicine approaches. Major trends in the forecast period include  diagnostic advances, new drug development, emerging therapies, collaborations for drug development, integration of ai.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/postmenopausal-osteoporosis-treatment-global-market-report

Segmentation & Regional Insights
The postmenopausal osteoporosis treatment market covered in this report is segmented –
1) By Drug Type: Bisphosphonates, Vitamin D3, Estrogen Agonist Or Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy, Other Drug Types
2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

North America was the largest region in the postmenopausal osteoporosis treatment market in 2023. The regions covered in the postmenopausal osteoporosis treatment  market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12680&type=smp

Major Driver Impacting Market Growth
The increasing prevalence of osteoporosis is expected to propel the growth of the postmenopausal osteoporosis treatment market going forward. Osteoporosis is a medical disorder resulting in decreased bone mass and deteriorated bone tissue, increasing weakness, and fracture risk. Postmenopausal osteoporosis treatment helps prevent or manage the condition and reduces the risk of fractures, improving the quality of life and overall health outcomes for affected individuals. For instance, in September 2022, according to Healthy Bones Australia, an Australia-based non-governmental organization, the number of fractures caused by osteoporosis or osteopenia increased from 178,439 fractures in 2021 to 183,105 in 2022. Therefore, the increasing prevalence of osteoporosis is driving the growth of the postmenopausal osteoporosis treatment market.

Key Industry Players
Major companies operating in the postmenopausal osteoporosis treatment  market report are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche AG, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Eli Lilly and Company, Amgen Inc., Asahi Kasei Corporation, Viatris Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Sandoz International GmbH, Fresenius Kabi AG, Daiichi Sankyo Company Ltd., Sun Pharmaceutical Industries Ltd., Cipla Inc., Dr.Reddys Laboratories Ltd., Hikma Pharmaceuticals PLC., Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Takeda Pharmaceutical Company Limited, Lupin Limited, Celltrion Inc., Biocon Limited, Accord Healthcare Ltd, Ligand Pharmaceuticals Incorporated, Torrent Pharmaceuticals Limited.

The postmenopausal osteoporosis treatment market report table of contents includes:
1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis

Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model